Toward non-parametric and clinically meaningful moderators and mediators

Statistics in Medicine

Volumn 27, Issue 10, 2008, Pages 1679-1692

  Kraemer, Helena Chmura ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

AUC; Mediator; Moderator; RCT

Indexed keywords

AREA UNDER THE CURVE; ARTICLE; MEDICAL RESEARCH; METHODOLOGY; NONPARAMETRIC TEST; RANDOMIZATION; RISK FACTOR; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE;

BIOMEDICAL RESEARCH; CAUSALITY; DATA INTERPRETATION, STATISTICAL; EFFECT MODIFIERS (EPIDEMIOLOGY); HUMANS; LINEAR MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; STATISTICS, NONPARAMETRIC;

EID: 42449101871     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3149     Document Type: Article

References (43)

1. Cohen J. The Earth is round (p<.05). American Psychologist 1995; 49:997-1003.
2. Dar R, Serlin RC, Omer H. Misuse of statistical tests in three decades of psychotherapy research. Journal of Consulting and Clinical Psychology 1994; 62:75-82.
3. Hunter JE. Needed: a ban on the significance test. Psychological Science 1997; 8(1):3-7.
4. Krantz DH. The null hypothesis testing controversy in psychology. Journal of the American Statistical Association 1999; 44(448):1372-1381.
5. Schmidt FL. Statistical significance testing and cumulative knowledge in psychology: implications for training of researchers. Psychological Methods 1996; 1(2):115-129.
6. Shrout PE. Should significance tests be banned? Introduction to a special section exploring the pros and cons. Psychological Science 1997; 8(1):1-2.
7. Thompson B. Journal editorial policies regarding statistical significance tests: heat is to fire as p is to importance. Educational Psychology Review 1999; 11:157-169.
8. Wilkinson L. The Task Force on Statistical Inference. Statistical methods in psychology journals: guidelines and explanations. American Psychologist 1999; 54:594-604.
9. Borenstein M. Hypothesis testing and effect size estimation in clinical trials. Annals of Allergy, Asthma, and Immunology 1997; 78:5-16.
10. Borenstein M. The shift from significance testing to effect size estimation. In Research & Methods, Comprehensive Clinical Psychology, Hersen M (ed.). Elsevier: Burlington, MD, 1998; 319-349.
11. Kraemer HC. Reporting the size of effects in research studies to facilitate assessment of practical or clinical significance. Psychoneuroendocrinology 1993; 17:527-536.
12. Kraemer HC, Kazdin AE, Offord DR, Kessler RC, Jensen PS, Kupfer DJ. Measuring the potency of a risk factor for clinical or policy significance. Psychological Methods 1999; 4(3):257-271.
13. Kraemer HC, Morgan GA, Leech NL, Gilner JA, Vaske JJ, Harmon RJ. Measures of clinical significance. Journal of the American Academy of Child and Adolescent Psychiatry 2003; 42(12):1524-1529.
14. Grissom RJ, Kim JJ. Effect Sizes for Research. Lawrence Erlbaum: Mahwah, NJ, 2005.
15. Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biological Psychiatry 2006; 59(11):990-996.
16. Kraemer HC, Stice E, Kazdin A, Kupfer D. How do risk factors work together to produce an outcome? Mediators, moderators, independent, overlapping and proxy risk factors. The American Journal of Psychiatry 2001; 158:848-856.
17. Kraemer HC, Wilson GT, Fairburn CG, Agras WS. Mediators and moderators of treatment effects in randomized clinical trials. Archives of General Psychiatry 2002; 59:877-883.
18. Kraemer HC, Frank E, Kupfer DJ. Moderators of treatment outcomes: clinical, research, and policy importance. Journal of the American Medical Association 2006; 296(10):1-4.
19. Kraemer HC. Correlation coefficients in medical research: from product moment correlation to the odds ratio. Statistical Methods in Medical Research 2007; 15(6):525-545.
20. Acion L, Peterson JJ, Temple S, Arndt S. Probabilistic index: an intuitive non-parametric approach to measuring the size of treatment effects. Statistics in Medicine 2006; 25(4):591-602.
21. Newcombe RG. A deficiency of the odds ratio as a measure of effect size. Statistics in Medicine 2006; 25:4235-4240.
22. Newcombe RG. Confidence intervals for an effect size measure based on the Mann-Whitney statistic. Part 1: general issues and tail area based methods. Statistics in Medicine 2006; 25(4):543-557.
23. Morgan GA, Gliner JA, Harmon RJ. Understanding and Evaluating Research in Applied and Clinical Settings. Lawrence Erlbaum: Mahwah, NJ, 2006.
24. Wen L, Badgett R, Cornell J. Number needed to treat: a descriptor for weighing therapeutic options. American Journal of Health-System Pharmacy 2005; 62(1):2031-2036.
25. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. Journal of Personality and Social Psychology 1986; 51:1173-1182.
26. Kraemer HC, Kiernan M, Essex MJ, Kupfer DJ. How and why criteria defining moderators and mediators differ between the Baron & Kenny and MacArthur approaches. Health Psychology, 2007, in press.
27. Cohen J, Cohen P, West S, Aiken L. Applied Multiple Regression/ Correlation Analysis for the Behavioral Sciences. Lawrence Erlbaum: Hillsdale, NJ, 2003.
28. Kraemer HC, Blasey C. Centering in regression analysis: a strategy to prevent errors in statistical inference. International Journal of Methods in Psychiatric Research 2004; 13(3):141-151.
29. Grissom RJ. Probability of lhe superior outcome of one treatment over another. Journal of Applied Psychology 1994; 79:314-316.
30. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143:29-36.
31. McGraw KO, Wong SP. A common language effect size statistic. Psychological Bulletin 1992; 111:361-365.
32. Hsu LM. Biases of success rate differences shown in binomial effect size displays. Psychological Bulletin 2004; 9(2):183-197.
33. Cook RJ, Sackett DL. The njtmber needed to treat: a clinically useful measure of treatment effect. British Medical Journal 1995; 310:452-454.
34. Altman DG. Confidence intervals for the number needed to treat. British Medical Journal 1998; 317(7168): 1309-1312.
35. Newcombe RG. Confidence intervals for the number needed to treat-absolute risk reduction is less likely to be misunderstood. British Medical Journal 1999; 318:1765.
36. Brownie C. Estimating Pr(X < Y) in categorized data using 'ROC' analysis. Biometrics 1988; 44:615-621.
37. Efron B, Gong G. A leisurely look at the bootstrap, the jackknife, and cross-validation. The American Statistician 1983; 37:36-48.
38. Efron B, Tibshirani R. Computer-intensive statistical methods. Technical Report M.D. 174, Division of Biostatistics, Stanford University, Stanford, CA, April 1995.
39. Murphy GMJ, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonic transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Archives of General Psychiatry 2004; 61:1163-1169.
40. The MTA Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder. Archives of Journal Psychiatry 1999; 56:1088-1096.
41. Scheffe H. The Analysis of Variance. Wiley: New York, 1959.
42. Jones LV, Tukey JW. A sensible formulation of the significance test. Psychological Methods 2000; 5(4):411-414.
43. Meehl PE. Theory testing in psychology and physics: a methodological paradox. Philosophy of Science 1967; 34:103-115.